C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
- In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels
- 12/08/2024
|
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
- Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Steve Hoerter as a director.
- 11/20/2024
|
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates
- C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.55 per share a year ago.
- 10/31/2024
|
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 345,600 shares of the Company's common stock to one new employee (the “Inducement Grant”), with the grant made on October 28, 2024 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).
- 10/28/2024
|
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
- Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience Overseeing Drug Discovery and Expansion of Leading Discovery and Clinical Portfolios
- 10/15/2024
|
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
- WATERTOWN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced its participation in the 7th Annual Targeted Protein Degradation & Induced Proximity Summit, to be held October 28-31, 2024, in Boston, MA. Four members of the company's leadership team will deliver oral presentations or participate on panels to demonstrate the company's expertise in designing and developing highly catalytic orally bioavailable degraders that have the potential to transform patients' lives.
- 10/09/2024
|
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- WATERTOWN, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 146,880 shares of the Company's common stock to one new employee (the “Inducement Grant”), with the grant made on September 30, 2024 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).
- 09/30/2024
|
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
- CFT1946 Is Well-Tolerated at All Dose Levels; No Dose-Limiting Toxicities CFT1946 Achieves Dose Proportional Pharmacokinetic Exposure; Successfully Degrades BRAF V600 Mutant Protein Early Evidence of CFT1946 Monotherapy Anti-Tumor Activity in Patients Who Have Progressed on or After BRAF Inhibitor Therapies; Majority of Patients Demonstrated Tumor Reduction Across V600 Mutation Types CFT1946 Global Phase 1 Trial Continues to Enroll; Monotherapy and Combination Expansion Cohorts Advancing With Additional Data Expected in 2025 C4T To Host Webcast Today at 12:00 pm ET; Webcast Link Available Here WATERTOWN, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced initial clinical data from the ongoing clinical trial of CFT1946, an orally bioavailable small molecule degrader of BRAF V600 mutations in solid tumors.
- 09/13/2024
|
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
- Abstract Released Today Highlights Favorable Safety Profile and Early Evidence of Monotherapy Anti-Tumor Activity Investor Webcast to be Held Friday, September 13, 2024 at 12:00 pm ET WATERTOWN, Mass., Sept. 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the abstract sharing clinical data from its ongoing Phase 1 clinical trial of CFT1946, a novel BiDAC™ degrader, in mutant BRAF V600 solid tumors, was released in conjunction with the ESMO Congress 2024 scheduled for September 13 – 17, 2024 in Barcelona, Spain.
- 09/08/2024
|
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
- WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Stephen (Steve) Fawell, Ph.D. as a director. With this appointment, Malcolm Salter has decided to retire from the Board of Directors after nearly a decade of service.
- 09/03/2024
|
C4 Therapeutics to Participate in Upcoming September Investor Conferences
- WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in fireside chats at two September investor conferences.
- 08/29/2024
|
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
- C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.73 per share a year ago.
- 08/01/2024
|
C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Preliminary Monotherapy Data from the Ongoing CFT1946 Phase 1 Trial in BRAF V600X Solid Tumors to be Presented at ESMO Congress 2024; Initiated Monotherapy Expansion Cohort in Melanoma and Combination Cohort with Cetuximab in Colorectal Cancer
- 08/01/2024
|
C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?
- C4 Therapeutics (CCCC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 07/17/2024
|
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
- WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing Phase 1/2 clinical trial of CFT1946, a novel BiDAC™ degrader in mutant BRAF V600 solid tumors, will be presented as a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 taking place September 13 – 17, 2024 in Barcelona, Spain.
- 07/16/2024
|
C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why
- C4 Therapeutics (CCCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 07/09/2024
|
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
- WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the UBS Targeted Protein Degradation (TPD) Day taking place virtually on July 15, 2024.
- 07/08/2024
|
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
- Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform the Board to Lead C4T into Next Phase of Growth WATERTOWN, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced changes to its Board of Directors as part of the Company's aspiration to become a fully integrated biotechnology company.
- 06/10/2024
|
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned Established a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Focused on Two Critical Oncogenic Proteins Progressed Phase 1 Dose Escalation Trials for Cemsidomide (CFT7455) and CFT1946; Data from Both Trials Expected in 2H 2024 Cash, Cash Equivalents and Marketable Securities Total $299.2 Million as of March 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the first quarter ended March 31, 2024, as well as recent business highlights.
- 05/08/2024
|
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 146,880 shares of the Company's common stock to one new employee (the “Inducement Grant”), with the grant made on April 29, 2024 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).
- 04/29/2024
|
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
- WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the Stifel 2024 Targeted Oncology Forum taking place virtually from April 16 – April 17, 2024.
- 04/09/2024
|
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
- WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, presented a poster today at the American Association for Cancer Research (AACR) Annual Meeting 2024 highlighting new preclinical data for CFT1946 across multiple models of BRAF V600X mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC), additional BRAF inhibitor (BRAFi)-resistant melanoma models, and an intracranial model of BRAF V600E metastatic melanoma.
- 04/08/2024
|
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
- CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis
- 03/05/2024
|
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
- Collaboration Focused on Two Targeted Protein Degraders from C4T's Internal Discovery Pipeline C4T to Receive a $16 Million Upfront Payment; Merck KGaA, Darmstadt, Germany, to Cover Discovery Research Costs Under the Collaboratio n C4T Eligible for up to Approximately $740 Million in Discovery, Development and Commercial Milestone Payments, in Addition to Future Royalties, Across Entire Collaboration WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced it has entered into a license and collaboration agreement with Merck KGaA, Darmstadt, Germany, which operates its healthcare business as EMD Serono in the U.S. and Canada, to exclusively discover two targeted protein degraders against critical oncogenic proteins that C4T has progressed within its internal discovery pipeline.
- 03/04/2024
|
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates
- C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.76 per share a year ago.
- 02/22/2024
|
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- CFT1946 Preclinical Data Accepted for a Poster Presentation at the AACR Annual Meeting 2024 Phase 1 Dose Escalation Trials for CFT7455 and CFT1946 Continue to Progress; Data from Both Trials Expected in 2H 2024 Well Capitalized with Cash Runway Expected into 2027 WATERTOWN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the year ended December 31, 2023, as well as recent business updates.
- 02/22/2024
|
C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?
- When C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company, reports fourth-quarter results, the focus will primarily be on pipeline progress.
- 02/15/2024
|
C4 Therapeutics, Inc. (CCCC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
- C4 Therapeutics, Inc. (CCCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/15/2024
|
C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn
- The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.
- 01/11/2024
|
C4 Therapeutics, Inc. (CCCC)'s Technical Outlook is Bright After Key Golden Cross
- From a technical perspective, C4 Therapeutics, Inc. (CCCC) is looking like an interesting pick, as it just reached a key level of support. CCCC's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
- 01/09/2024
|
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
- Multiple 2024 Clinical Updates Expected, Including Data from the Ongoing CFT7455 and CFT1946 Phase 1 Dose Escalation Trials
- 01/09/2024
|
C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals
- WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the closing of the previously announced $25 million stock purchase agreement with a wholly-owned subsidiary of Betta Pharmaceuticals Co. Ltd (Betta) (300558.SZ), a leading pharmaceutical company focusing on the development of innovative oncology therapies in China. This investment was completed at $4.49 per share. The purchase price represents a 25% premium over the 60-trading-day volume weighted average through the date that was two business days prior to the entry into the stock purchase agreement on May 29, 2023.
- 01/04/2024
|
C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the Company will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Thursday, January 11 at 9:00 am PST (12:00 pm EST).
- 01/04/2024
|
C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why
- C4 Therapeutics (CCCC) shares surge on a licensing deal to develop degrader-antibody conjugates with Merck and positive data from CFT7455 studies.
- 01/03/2024
|
Wall Street Analysts See a 197.7% Upside in C4 Therapeutics, Inc. (CCCC): Can the Stock Really Move This High?
- The mean of analysts' price targets for C4 Therapeutics, Inc. (CCCC) points to a 197.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 01/01/2024
|
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
- We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024 following signals of a stabilizing market.
- 12/27/2023
|
C4 Therapeutics blasts off: what's next?
- As the market soars to new heights, with capital fast flowing back into the small-cap, more speculative, and traditionally risky investments and sectors, C4 Therapeutics NASDAQ: CCCC has become the latest small-cap stock to surge higher in price.
- 12/18/2023
|
Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 222.95%: Read This Before Placing a Bet
- The mean of analysts' price targets for C4 Therapeutics, Inc. (CCCC) points to a 223% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 12/15/2023
|
C4 Therapeutics (CCCC) Soars on Oncology Deal With Merck
- C4 Therapeutics (CCCC) inks an agreement with Merck to discover and develop degrader-antibody conjugates with a focus on one oncology target. Shares rise on the same.
- 12/13/2023
|
Throw away those target-date funds, and don't hold bonds at all, says this daring new research
- The last Fed meeting of the year is upon us, as those record highs for stock markets just keep coming. Can the Fed keep those fires burning?
- 12/13/2023
|
C4 Therapeutics stock soars on Merck partnership, license deal
- C4 Therapeutics Inc shares surged 93% to $2.28 in early trading on Tuesday after the clinical-stage biopharmaceutical company announced an exclusive license and collaboration agreement with Merck to develop degrader-antibody conjugates (DACs), an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells. C4 said it will receive a $10 million upfront payment and is eligible to receive milestone payments totaling about $600 million, as well as tiered royalties on future sales.
- 12/12/2023
|
Why Is C4 Therapeutics (CCCC) Stock Up 72% Today?
- C4 Therapeutics (NASDAQ: CCCC ) stock is heading higher on Tuesday as investors in the clinical-stage biopharmaceutical company celebrate a new license and research collaboration with Merck (NYSE: MRK ). This exclusive agreement with Merck has C4 Therapeutics working with it to develop degrader-antibody conjugates (DACs).
- 12/12/2023
|
C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma
- WATERTOWN, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that it will host a webcast on Tuesday, December 12, 2023 at 4:30 PM ET to present new Phase 1 dose escalation data for relapsed refractory multiple myeloma from the ongoing Phase 1/2 clinical trial of CFT7455, a MonoDAC™ degrader of IKZF1/3, for the potential treatment of relapsed/refractory multiple myeloma and relapsed/refractory non-Hodgkin's lymphoma.
- 11/28/2023
|
Here's Why C4 Therapeutics, Inc. (CCCC) Looks Ripe for Bottom Fishing
- C4 Therapeutics, Inc. (CCCC) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
- 11/13/2023
|
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
- C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $0.65 per share a year ago.
- 05/04/2023
|
Down -29.73% in 4 Weeks, Here's Why You Should You Buy the Dip in C4 Therapeutics, Inc. (CCCC)
- C4 Therapeutics, Inc. (CCCC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 04/11/2023
|
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates
- C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -5.56% and 66.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/23/2023
|
C4 Therapeutics to Present at Two Virtual February 2023 Conferences
- WATERTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that C4T management will participate in a fireside chat and a panel discussion at two upcoming virtual conferences in February.
- 02/08/2023
|
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the Company will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9th at 10:30 am PST (1:30 pm EST).
- 01/03/2023
|
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates
- C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 0% and 30.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/03/2022
|
C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022
- WATERTOWN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that C4T management will participate in a fireside chat at the virtual Bank of America Securities Precision Oncology Conference 2022.
- 09/26/2022
|
C4 Therapeutics: Poor Data Destroyed Preclinical Promise
- CCCC showed a lot of preclinical promise for its protein degrader platform. However, first clinical data presented at AACR has destroyed the stock.
- 05/04/2022
|
Why C4 Therapeutics Stock Is Plunging Today
- C4 Therapeutics Inc (NASDAQ: CCCC) shares are trading significantly lower Friday afternoon after the company presented data from Cohort A of its ongoing Phase 1/2 clinical trial of CFT7455. Cohort A, the first cohort in the clinical trial, explored CFT7455 as a single agent and enrolled five.
- 04/08/2022
|
C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial
- C4 Therapeutics Inc (NASDAQ: CCCC) has presented data from Cohort A of its ongoing Phase 1/2 trial of CFT7455 for multiple myeloma (MM) and non-Hodgkin's lymphomas (NHL). The data will be presented at the American Association for Cancer Research (AACR) Annual Meeting.
- 04/08/2022
|
C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022
- - Clinical Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted as Late-Breaker Poster Presentation –
- 03/08/2022
|
C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
- WATERTOWN, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 10:30 a.m. EST.
- 01/03/2022
|
What Makes C4 Therapeutics, Inc. (CCCC) a New Buy Stock
- C4 Therapeutics, Inc. (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 12/29/2021
|
C4 Therapeutics (CCCC) Sees Hammer Chart Pattern: Time to Buy?
- C4 Therapeutics (CCCC) has been struggling lately, but the selling pressure may be coming to an end soon.
- 12/01/2021
|
C4 Therapeutics, Inc. (CCCC) Moves to Buy: Rationale Behind the Upgrade
- C4 Therapeutics, Inc. (CCCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 11/22/2021
|
Why C4 Therapeutics (CCCC) Might Surprise This Earnings Season
- C4 Therapeutics (CCCC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 11/10/2021
|
C4 Therapeutics Multiple Myeloma Candidate Scores FDA Orphan Drug Tag
- The FDA has granted Orphan Drug Designation to C4 Therapeutics Inc (NASDAQ: CCCC) CFT7455 for multiple myeloma. CFT7455 is an orally bioavailable MonoDAC degrader targeting IKZF1/3.
- 08/12/2021
|
C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
- – Dosed First Patient in Phase 1/2 Clinical Trial of CFT7455, a novel IKZF1/3 Degrader, in Hematologic Malignancies; Data Expected in 2022 –
- 08/11/2021
|
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma
- WATERTOWN, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to CFT7455 for the treatment of multiple myeloma.
- 08/11/2021
|
C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
- WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced the closing of an underwritten public offering of 4,887,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 637,500 shares of common stock, at a public offering price of $37.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $180.8 million. All of the shares in the offering were offered by C4T.
- 06/21/2021
|
C4 Therapeutics Announces Pricing of Public Offering
- WATERTOWN, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced the pricing of an underwritten public offering of 4,250,000 shares of its common stock at a public offering price of $37.00 per share.
- 06/16/2021
|
C4 Therapeutics Launches Proposed Public Offering
- WATERTOWN, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that it has launched a proposed public offering of 4,250,000 shares of its common stock.
- 06/14/2021
|
C4 Therapeutics Appoints Lauren White as Chief Financial Officer
- WATERTOWN, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced the appointment of Lauren White to the role of chief financial officer, effective June 21, 2021. Ms. White's appointment will initiate William (Bill) McKee's planned transition from interim chief financial officer, a role he has held since March 31, 2020. Mr. McKee will remain engaged to support C4T in a part-time consulting capacity to ensure a smooth transition.
- 05/20/2021
|
C4 Therapeutics to Present at Upcoming Investor Conferences
- WATERTOWN, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will participate in the following upcoming investor conferences:
- 05/12/2021
|
C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the AACR Annual Meeting 2021
- – CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across a Panel of Multiple Myeloma Cell Lines Including IMiD-Resistant Models –
- 04/10/2021
|
C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial Results
- – Phase 1/2 Trial for Lead Candidate CFT7455, a MonoDAC™ Degrader Targeting IKZF1/3 for the Treatment of Hematologic Malignancies, On Track for 1H 2021 Initiation Following FDA Clearance of Investigational New Drug (IND) –
- 03/11/2021
|
C4 Therapeutics to Present on the Discovery and Preclinical Development of CFT7455, a MonoDAC™ Degrader Targeting IKZF1/3, at the American Association for Cancer Research (AACR) Annual Meeting
- WATERTOWN, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that a late-breaking abstract featuring preclinical data for CFT7455 has been selected for presentation at the first session of the American Association for Cancer Research (AACR) 2021 Annual Meeting, being held virtually April 10-15, 2021. CFT7455, the Company's most advanced protein degrader, targets IKZF1/3 for the treatment of hematologic malignancies.
- 03/10/2021
|
C4 Therapeutics to Participate in Upcoming March Investor Conferences
- WATERTOWN, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will participate in the following upcoming March investor conferences:
- 02/24/2021
|
C4 Therapeutics to Participate in BMO BioPharma Spotlight Series
- WATERTOWN, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will participate in the BMO BioPharma Spotlight Series: Proteins – Degraders and Other Next Gen Technologies, including a panel discussion, “Ligating” Competitors for Collaboration in the Protein Degradation Space, on Thursday, February 18, 2021 at 10:30 a.m. ET.
- 02/11/2021
|
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an Orally Bioavailable MonoDAC for Hematologic Malignancies
- – Phase 1/2 Clinical Study of CFT7455 Expected to Initiate in 1H 2021 – – Phase 1/2 Clinical Study of CFT7455 Expected to Initiate in 1H 2021 –
- 01/19/2021
|
C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022
- – Investigational New Drug (IND) Application for Lead Candidate CFT7455, a MonoDAC™ targeting IKZF1/3 for the Treatment of Hematologic Malignancies, Under FDA Review; Initiation of Phase 1/2 Trial Expected in 1H 2021 –
- 01/06/2021
|
C4 Therapeutics: Preclinical Stage Protein Degrader Developer With A Differentiated Approach
- C4 Therapeutics, along with a host of others, is developing therapeutics in the cutting edge field of protein degraders. Blockbuster drugs like Revlimid and Pomalyst are now known to be protein degraders.
- 12/27/2020
|
U.S. IPO Weekly Recap: IPO Launches And Filings Abound In The Post-Labor Day Frenzy
- One IPO and nine SPACs went public this past week. Thirteen IPOs and eleven SPACs submitted initial filings as the IPO market gears up for a busy September.
- 09/13/2020
|
